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In Brief
Dmitrieva-Posocco et al. use conditional gene deletion approaches in a model of colorectal cancer and find that IL-1 has distinct effects on different cell types in the tumor microenvironment. The tumorpromoting effects of IL-1 are both inflammation dependent and independent, whereas its tumorsuppressive effects rely on neutrophilmediated control of bacterial invasion.
INTRODUCTION
A particularly important component of the pro-tumorigenic microenvironment is the presence of inflammatory cells and the subsequent chronic inflammatory response. Although chronic inflammation is a well-established driver in many cancers (Mantovani et al., 2008) , inflammation also appears to play a deleterious role in cancers without overt underlying inflammatory etiologies. This phenomenon, characterized by a tumor's ability to recruit inflammatory immune cells to the local microenvironment to drive both tumor growth and progression, is referred to as tumor-elicited inflammation (TEI) (Grivennikov et al., 2012) . The relevance of TEI is illustrated by the efficacy of anti-inflammatory treatments in reducing mortality from cancers that are classically thought of as ''non-inflammatory'' (Rothwell et al., 2012) .
In sporadic colorectal cancer (CRC), the breakdown of the epithelial barrier subsequent to oncogenic transformation leads to the translocation of bacterial products and triggers the interleukin (IL)-23-IL-17A signaling pathway (Grivennikov et al., 2012) . Increased amounts of these cytokines within tumors portends poor prognosis in CRC patients (Tosolini et al., 2011) and promotes CRC in various animal models (Blatner et al., 2012; Grivennikov et al., 2012; Huber et al., 2012; Kirchberger et al., 2013) . In humans and mice, however, not all tumors expressing high amounts of the pro-tumorigenic cytokine IL-23 have commensurately high IL-17A expression, implying that other regulators of TEI exist. Overall, a complete mechanistic understanding of TEI induction, its maintenance, and its contribution to tumorigenesis is lacking.
IL-1 plays an essential role in inducing IL-17 production by T helper (Th17) cells in both humans and mice in the context of inflammation and autoimmunity (Coccia et al., 2012; Zhou and Littman, 2009 ). Approaches to block the IL-1 pathway are being used to treat inflammatory conditions such as rheumatoid arthritis, gout, and familial Mediterranean fever (Dinarello et al., 2012) . Despite its well-known role in maintaining immune-mediated inflammatory responses, the role of IL-1 signaling as a regulator of TEI and CRC in autochthonous models is obscure. IL-1 signaling is implicated in the generation of both pro-or anti-tumor immune responses, as well as in the development of intestinal inflammation linked to tumorigenesis (Bersudsky et al., 2014; Malik et al., 2016; Voronov et al., 2003) . A recent CANTOS trial testing the ability of the anti-IL-1b antibody canakinumab to prevent adverse cardiovascular events revealed a protective effect of systemic IL-1b inhibition in lung cancer, but not colon cancer (Ridker et al., 2017) . Gating strategy is indicated on the panels.
(legend continued on next page)
Here, we used cell-type-specific inactivation of IL-1R1 to examine the impact of IL-1 on distinct cells within the CRC tumor microenvironment. IL-1 signaling controlled CRC development and progression by three distinct mechanisms. In epithelial cells, IL-1 signaling directly drove tumorigenesis without affecting inflammatory responses. Deletion of Il1r1 in T cells blocked IL-17 and IL-22 production, reducing TEI and blunting CRC tumorigenesis. These pro-tumorigenic effects of IL-1 were countered by IL-1 signaling in myeloid cells, specifically neutrophils. Deletion of Il1r1 in myeloid cells resulted in increased infiltration of bacteria into the tumor tissue, and the triggering of a pro-tumorigenic inflammatory response resembling tumor elicited inflammation. The complex effects of IL-1 in distinct cell type within the tumor microenvironment may underlie the distinct results in bacteriarich and other cancers upon IL-1 blockade.
RESULTS

Increased IL-1a and IL-1b Expression in CRC Tumors Promotes IL-17A Responses
We operated under the premise that potential regulators of TEI should be increased in tumor tissue and should be able to control processes associated with inflammatory responses in a variety of cell types. We used the CDX2Cre-Apc f/wt (CPC-APC) mouse model of conditional monoallelic APC loss in the colon to induce CRC. We found elevated Il1a, Il1b, and Il17a gene expression in tumors compared to normal colon tissue ( Figure 1A ). Multiplex assay of tumor culture supernatants showed increased protein concentration of all three cytokines, compared to matched normal tissues ( Figure 1B ). Other members of the IL-1 cytokine family were detected in CRC ( Figure S1A and S1B). FACS sorting of specific cell populations from normal and tumor tissue with subsequent qRT-PCR analysis revealed that monocytes are the main source of IL-1a and IL-1b ( Figure S1C ), although tumor epithelial and stromal cells also were producing IL-1 ( Figure S1D ).
Data from in vitro models of mouse and human Th17 cell differentiation, and from in vivo models of chronic inflammation, positions IL-1 as an important regulator of Th17 differentiation and IL-17A production (Chung et al., 2009; Coccia et al., 2012) . Therefore, we sought to examine whether IL-1 signaling is required for generating and maintaining the IL-17A TEI responses in CRC. To check whether pharmacological blockade of IL-1 signaling resulted in decrease of TEI cytokines in vivo, we injected reporter CPC-APC-Il17a GFP+/À mice i.p. with the recombinant IL-1R
antagonist Anakinra (IL-1Ra) for 3 consecutive days. Two hours after the last injection, tumors and normal tissues were isolated and subjected to qRT-PCR and flow cytometry analyses. In tumor tissue, qRT-PCR analysis revealed a significant drop in mRNA expression for Il17a, its transcription factor Rorc and another TEI-related cytokine Il22 compared to normal colon (Figure 1C) . IL-17A-GFP reporter expression was confined to various lymphoid ( Figure 1D ) but not epithelial, stromal, or myeloid cells ( Figure S1E ). IL-1Ra treatment significantly reduced IL-17A-GFP reporter expression by the lymphoid cells ( Figures 1D and  1E ). Therefore IL-1 signaling is required for IL-17A and TEI cytokine expression and even short-term inhibition of IL-1 resulted in reduction of intratumoral IL-17A and TEI in CRC. CPC-APC controls were allowed to spontaneously develop CRC. Genetic ''whole-body'' ablation of IL-1R1 resulted in significant drop of Il17a, Rorc, and Il22 mRNAs ( Figure 1F ). Flow cytometry analysis of intratumoral LPL and IEL fractions from Il1r1 À/À CPC-APC-Il17a GFP+/À reporter mice revealed that IL-17A expression was reduced in the absence of IL-1 signaling ( Figure 1G ).
We and others previously reported that inactivation of IL-17A, RORgt, or IL-22 results in a prominent reduction in CRC (Blatner et al., 2012; Grivennikov et al., 2012; Huber et al., 2012; Kirchberger et al., 2013; Wu et al., 2009 ). Thus, we expected that the significant decrease in IL-17A and IL-22 cytokine expression in Il1r1 À/À CPC-APC mice would culminate in reduced CRC. However, tumor multiplicity was only modestly reduced and tumor size was not affected by IL-1R1 deficiency, leaving tumor load essentially unchanged ( Figures 1H and 1I) .
As hematopoietic cells are the main source of IL-17A and IL-22 ( Figures 1D and S1E ), hypothetically the ability of IL-1 to regulate TEI should be more evident within the hematopoietic compartment. Therefore, we lethally irradiated 6-week-old CPC-APC mice and reconstituted them with bone marrow (BM) from Il1r1 À/À and Il1r1 +/+ control mice. Similarly, to what we observed in the whole-body Il1r1 deficiency, lack of IL-1R1 on hematopoietic cells led to a significant decrease in Il17a, Rorc, and Il22 mRNA expression and protein release (Figures S2A and S2B and data not shown) in CRC tumors. Intracellular cytokine staining confirmed the reduction in protumorigenic IL-17A ( Figures S2C and S2D) ; however, hematopoietic IL-1R1 deficiency did not affect CRC tumor development ( Figures 1J and S2E ).
To confirm these unexpected results, we used an inducible CRC model, CDX2-ERCre (CDX2ERT)-Apc f/f , where bi-allelic deletion of the Apc gene and rapid development of CRC tumors are driven by injection of tamoxifen (Feng et al., 2013; Wang et al., 2014 deficiency of IL-1 signaling ( Figure S2F ) whereas TEI factors Il17a, Rorc and Il22 expression were reduced ( Figure S2G ), as was the production of the IL-17A protein ( Figure S2H ). Together, the results from two models of CRC revealed that IL-1 signaling in hematopoietic cells controlled key components of TEI, but global or hematopoietic cell specific ''blanket'' inactivation of IL-1R did not significantly alter CRC tumorigenesis. Figure S3A ). We found that epithelial specific IL-1R1 inactivation resulted in a pronounced reduction in CRC multiplicity and load (Figures 2A-2C ). These changes were not linked to alterations in TEI cytokine responses, as intratumoral mRNA expression of Il17a, Il17f, Rorc, and Il22 were indistinguishable between epithelial Il1r1 deficient mice (D/f) and control (D/WT) mice ( Figure 2D ). Therefore, epithelialspecific Il1r1 deletion uncouples the role of IL-1 signaling in TEI induction from its role in direct tumor promotion in colonic epithelial cells. The direct effect of IL-1 signaling in epithelial cells on CRC was linked to epithelial cell proliferation, as Ki-67 staining revealed that tumors from young
IL-1R1
-CPC-APC) mice were less proliferative ( Figures 2E and 2F ), resulting in tumor size trending lower than in controls ( Figure 2G Figures 2H and 2I ). Mechanistically, epithelial Il1r1 deficiency led to a decreased nuclear accumulation of the NF-kB p65 subunit in the tumor epithelial fraction in both the inducible ( Figure 2J ) and spontaneous models ( Figure S3C ). Thus, IL-1R in a cell autonomous manner is essential for NF-kB activation in the tumor epithelium. Proliferation of early tumor seeds was also reduced in vivo in the absence of epithelial IL-1R signaling ( Figures S3D and S3E ). As NF-kB (Schwitalla et al., 2013) and IL-1b in vitro (Kaler et al., 2009) Figure 3F ); and mRNA of Rorc and Il17a in T cells were correspondingly reduced ( Figures S4C and S4D ). In mice lacking IL-1R1 on T cells, well developed CRC tumors did not show obvious differences in Ki-67 expression compared to wild-type controls ( Figures 3G and 3H ). However, activation of the oncogenic factor STAT3 in tumor cells was reduced (Figure 3I) , presumably via loss of STAT3 activating cytokine expression. A reduction in CRC was also observed in the inducible model of CRC ( Figures S4E-S4G ) accompanied by reduced Il17a, Rorc, and Il22 expression ( Figure S4H ). Therefore, IL-1 signaling in T cells was required for the expression of RORgt in tumors, which induced pro-tumorigenic cytokines IL-17A and IL-22 and TEI-driven tumorigenesis.
Myeloid Cell Specific IL-1 Signaling Controls Tumor Microbial Infiltration and Prevents CRC Development
Hematopoietic deletion of IL-1R1 did not alter CRC; however, its specific inactivation in T cells did reduce tumors. We therefore hypothesized that IL-1 signaling in an as-yet-unidentified hematopoietic population possesses an anti-tumorigenic role. We inactivated IL-1R1 in myeloid cells (monocytes, macrophages, and neutrophils) by creating CD11bCre-Il1r1 f/f mice and confirmed specific Il1r1 exon 5 deletion (Figures S5A and S5B) . We then used these mice to produce BM chimeras in CDX2ERT-Apc f/f mice, generating CRC-prone mice lacking IL-1R1 on myeloid cells (CD11bCre
) and controls (CD11bCre
. Surprisingly, mice lacking Il1r1 in myeloid cells had a higher tumor multiplicity and size ( Figures 4A-4C ) accompanied by increased cell proliferation ( Figure 4D ). Moreover, these tumors displayed increased inflammation, as determined by qRT-PCR analysis for Il17a, Il17f, Rorc, Ptgs2 (encodes for COX2), and Il22 ( Figure 4E ). In agreement, increased protein levels of IL-17A and IL-22 were detected in ex vivo tumor culture supernatants ( Figure 4F ).
Enhancement of Th17 inflammatory responses could not be explained by the lack of direct action of IL-1 on myeloid cells, as myeloid cells did not directly contribute to IL-17A production ( Figure S1D ). We therefore reasoned that IL-1R1 deficiency in myeloid cells triggered additional stimuli promoting IL-17A production. As various intestinal microbial species are essential for induction of IL-17A (Ivanov et al., 2009; Wu et al., 2009) , we tested whether alterations in CRC-associated microbes were responsible for the heightened CRC. qRT-PCR for generic bacterial 16S rRNA revealed an increased bacteria presence in tumors from mice lacking IL-1R1 on myeloid cells ( Figure 4G ) with specific increase in bacteria included E. coli, Enterobacteroides, and SFB ( Figure 4G ). We further tested whether short term IL-1 blockade with Anakinra (IL-1RA) would induce the same bacterial perturbations. Anakinra treatment for 12 days did increase bacterial infilitration of CRC tumors, particularly with E. coli ( Figure S5C ), but did not alter CRC tumorigenesis ( Figures S5D and S5E ). /CDX2ERT-Apc f/f and control mice with broad spectrum antibiotics for 4 weeks, starting after the epithelial transformation ( Figure 4H ). Ablation of intestinal and tumor associated microbiota resulted in a drastic reduction of CRC tumorigenesis in both control and myeloid IL-1R deficient mice ( Figure 4I and 4K). Bacterial 16S RNA, SFB 16S RNA, and Il17a mRNA in tumors from myeloid IL-1R1-deficient mice treated with antibiotics were strongly reduced compared to the untreated group (Figure 4K ). Importantly, difference in CRC was no longer observed between antibiotic-treated control and myeloid IL-1R1 deficient animals ( Figures 4J and 4K ).
To ascertain whether increased IL-17A/IL-22 response in tumors in mice lacking IL-1R1 in myeloid cells was driven in part by increased IL-1 action in T cells and increased IL-17A production, we created CD11bCre-CD4Cre-Il1r1 f/f ''double Cre'' mice and then generated CRC-bearing BM chimeras. 5A and 5B).
The difference was even more notable when myeloid IL-1R1-deficient mice and controls were housed separately as cohousing typically allows microbiota equalization (Figures 5A and 5B) .
strated increased mRNA expression of Il17a, Il22, and Ptgs2 ( Figure 5C ), as well as bacterial 16S rRNA, E. coli, and SFB in tumors ( Figure 5D ). Moreover, Yo-Yo 1 DNA staining of wholemount colons revealed an increase in bacteria located on the immediate surface of the tumor ( Figure 5E Figure 5F ). This was largely confirmed by 16S qRT-PCR of naive colonic tissue ( Figure S5H ). CRC formation did induce differences in fecal microbiota between wild type and myeloid Il1r1 À/À mice, but that difference was not evident if mice were co-housed ( Figure 5F ). On the other hand, significant differences were detected in the microbiota composition of bacterial adherent to the tumor tissue, but not to the normal tissue in LysMCre + mice (Figures 5F and 5G , mice lacking IL-1R1 only in neutrophils demonstrated an increase in CRC when IL-1R-deficient and control mice were co-housed. Even stronger acceleration of CRC was detected when mice were housed separate ( Figures 6A and 6B) . Il17a, Il22, and Ptgs2 expression in tumors, as well as Il1a and Il1b expression in monocytes was increased in the absence of neutrophil-specific IL-1R signaling ( Figures 6C and 6D ) as was protein expression of both IL-17A and IL-22 (Figures 6E-6G) . We also detected an association of bacteria with CRC tumors (Figures 6H and 6I ) and an increased presence of distinct bacteria, including E. coli, inside CRC tumors ( Figure 6J ). No significant differences in bacteria adherent to the colonic epithelium in naive mice were Figure S7E ). Also, ex vivo experiments did not detect significant differences in intracellular levels of bactericidal ROS in neutrophils ( Figure S7F ), although for these experiments intratumoral neutrophils undergo mechanical isolation possibly resulting in their activation. CD11b + Ly6G + neutrophils, enriched or sorted from spleens, bone marrow, thioglycollate elicited peritoneal exudate or from CRC tumors, were able to kill various bacteria, including lab strain of E. coli and bulk fecal bacteria, upon IL-1b treatment. That ability was impaired when neutrophils were rendered IL-1R deficient (Figures 7C-7E ). We further found that the absence of functional IL-1R signaling led to a decreased ability of neutrophils to ingest zymosan particles or GFP-labeled Salmonella typhimurium bacteria ( Figures 7F-7I ). Expression of antimicrobial peptides was also reduced in the absence of IL-1R in neutrophils ( Figure 7J ). Overall our data suggested that neutrophils lacking IL-1R signaling have defective anti-bacterial functions. Together, these results underscore the importance of direct IL-1R signaling in neutrophils preventing tumor associated dysbiosis, over inflammation and CRC development.
DISCUSSION
Inflammatory cytokines are emerging as regulators of the tumor microenvironment through multiple mechanisms of action. Cytokines are also increasingly attractive targets in cancer because they are amenable to antibody-mediated neutralization without the toxicities of common chemotherapies. As more cytokines are found to be essential for tumor development, at least in pre-clinical models, it is expected that the number of cytokine blockers tested in cancer clinical trials will increase. However, whether the efficacy of anti-cytokine therapy might be suboptimal because of cytokine signals operating within a particular spatio-temporal context, remains unexplored.
Previous studies have demonstrated that genetic or pharmacologic blockade of a single pro-tumorigenic cytokine can cause an unambiguous reduction in CRC, because these TEI cytokines act on epithelial and cancer cells and drive tumor growth (Chae et al., 2010; Grivennikov et al., 2009; Wang et al., 2014) . Based on a vast literature implicating IL-1 signaling in the regulation of autoimmunity, inflammation, and specific induction of IL-17 production and differentiation of Th17 cells (Carmi et al., 2011; Nakae et al., 2003; Shaw et al., 2012) , we hypothesized that IL-1 driven signals would be essential for controlling TEI and thereby facilitating CRC growth. We found that whole body and hematopoietic cell-specific IL-1R1 ablation did decrease expression of TEI cytokines, but unexpectedly caused very limited, if any, decrease in CRC. This presented us with a conundrum of why inactivation of IL-1R signaling in the hematopoietic system did not tame CRC, despite a reduction in pro-tumorigenic cytokines whose inactivation reproducibly reduces CRC in a variety of experimental conditions (Blatner et al., 2012; Grivennikov et al., 2012; Kirchberger et al., 2013) . Given the multifaceted roles of IL-1R1 and the fact that IL-1R1 is expressed by virtually all cell types in the body, it was conceivable that IL-1 signaling may have opposing roles in different cell types. In this work we showed that in the CRC tumor microenvironment, IL-1 signaling plays distinct roles, depending on cell type, and established the cellular and molecular mechanisms governing how this particular cytokine regulated multipronged processes during intestinal tumorigenesis.
Analysis of epithelial-specific IL-1R1 deletion revealed a decrease in CRC tumor multiplicity, slower proliferation of early tumor seeds, and decreased activation of NF-kB. NF-kB is an essential regulator of cell survival and proliferation, and its inactivation in intestinal epithelial cells by deletion of IKKb kinase during the development of colitis-associated cancer decreases tumor multiplicity (Greten et al., 2004) . These observations are in line with reports that IL-1a and IL-1b stimulate growth in colon cancer cell lines in vitro and in xenograft transplants in vivo (Voronov et al., 2003; Holen et al., 2016) . While NF-kB can be activated by a plethora of stimuli, IL-1R signaling may be essential for activating NF-kB in CRC because IL-1a and IL-1b are rapidly released by transformed and stressed cells, as well as by cells stimulated with microbes infiltrating early tumors. IL-1 signaling in epithelium regulated early CRC, while being dispensable for the expression of inflammatory cytokines, indicating that IL-1 signaling controlled CRC in an inflammation-independent manner.
In T cells, IL-1 signaling regulated CRC in an inflammationdependent manner. Lymphoid cells, including T cells and ILC3, are important producers of IL-17A and other TEI cytokines during host defense and chronic inflammation. These lymphoid cells infiltrate CRC tumors and their increased presence correlates with poor prognosis in CRC patients, according to CRC ''Immunoscore'' (Bindea et al., 2013; Tosolini et al., 2011 ). Here we found that IL-1 signaling in T cells was essential for the production of IL-17A and IL-22 cytokines in CRC tumors, consistent with what has been observed in other inflammatory conditions in mice and humans (Shaw et al., 2012; Zhou and Littman, The novel observation of this work was that IL-1 signaling in myeloid cells is anti-tumorigenic, at least in the context of tumors growing at ''microbial-rich'' surfaces. IL-1R signaling in myeloid cells kept specific species/genera of tumor infiltrating microbes at bay and prevented local, tumor-specific dysbiosis and excessive amounts of pro-tumorigenic inflammatory cytokines. We propose that increased infiltration of ''bad'' (protumorigenic) and a decrease in ''good'' (anti-tumorigenic) gut bacteria led to an increased bacterial recognition by myeloid cells and production of IL-17A, which induces IL-1b and IL-23, along with other tumor-promoting inflammatory entities, which drive CRC. 16S rRNA sequencing of the microbiome had shown that the observed dysbiosis did not occur in naive mice and was induced in a tumor-specific manner.
Neutrophils but not monocytes or macrophages were essential to deter tumor-infiltrating bacteria and dampen CRC promoting inflammation. Neutrophils represent an important component of the tumor microenvironment, where they can be immunosuppressive as a form of myeloid derived suppressor cells or directly tumor promoting or anti-tumorigenic (Fridlender et al., 2009; Gabrilovich and Nagaraj, 2009) . While neutrophils are a key component of anti-microbial defense, here we found a tumor specific, anti-microbial role for neutrophils in cancer.
Previous work on Il1r1
À/À mice shows defective neutrophil recruitment and higher susceptibility to infection, with no change in bacterial killing assessed primarily in macrophages (Miller et al., 2006) . Here, we found that while lack of IL-1R on neutrophils did not alter neutrophil recruitment and its ability to form NET's, however, it led to defective bacterial killing. Thus, neutrophil-specific IL-1 signaling is critical for preventing tumor-associated dysbiosis, TEI and CRC, where bacteria are invasive due to the increased epithelial permeability and decreased mucus coverage. Significant alterations of commensal microbiota are present in mouse mutants devoid of IL-18 signaling and in various mutants affecting the inflammasome pathway (Elinav et al., 2011; Franchi et al., 2010) essential for IL-1b and IL-18 cytokine processing and activation, but altered microbiota have not been found in mice with global IL-1R1 deficiency. The IL-1 pathway has been extensively studied in the context of cancer, but often using cell-line-based non-autochthonous models, immunodeficient mice, or cancer models where epithelial surfaces are not rich in microbes. Levels of IL-1b are elevated in multiple cancers in human and mouse models, including colon, gastric, breast, non-small-cell lung carcinoma, and melanomas (Elaraj et al., 2006) . Genetic inactivation of IL-1R1 or caspase 1, a key enzyme in IL-1b processing, reduced tumorigenesis in a two-step skin cancer model (Drexler et al., 2012) . Inactivation of IL-1a and MyD88 reduces liver carcinogenesis in DEN model (Sakurai et al., 2008) . Blocking IL-1 signaling in human breast cancer xenografts or a mouse model of breast cancer results in changes in tumor growth and metastatic spread, and also in decreased infiltration by myeloid CD11b + Gr1 + cells (Dagenais et al., 2017; Holen et al., 2016) . Neutrophils and IL-1 signaling are critical for breast cancer metastasis but not primary tumor growth (Coffelt et al., 2015) , and environmental and dietary factors can drive inflammasome/IL-1 dependent breast cancer (Kolb et al., 2016) . Furthermore, in transplantable B16 melanoma and prostate cancer models, IL-1b was found to be essential for invasiveness and metastatic growth while the same function has been assigned to IL-1a in breast cancer (Voronov et al., 2003) . IL-1a and MyD88 signaling drive skin tumorigenesis (Cataisson et al., 2012) ; however, in the model of MCA-induced fibrosarcoma, IL-1a is essential for activation of antitumor responses (Elkabets et al., 2009 ). Moreover IL-1 can play a role of a ''danger signal,'' when released from necrotizing cells (Ghiringhelli et al., 2009) . Still, it remains to be determined whether IL-1 exerts its pro-tumorigenic signaling by induction of TEI or whether IL-1 signaling is largely autonomous to cancer cells. Recently, an IL-1a neutralizing antibody was tested in clinical trials for advanced CRC (Hickish et al., 2017) ; meanwhile a complete blockade of IL-1 signaling has been proposed but not thoroughly examined.
Propelled by numerous studies implicating inflammatory IL-1 signaling in cancer, several clinical studies with IL-1 antagonists as monotherapies and combination therapies for human cancers are underway. Our results, however, suggest that a more cautious approach may be required when considering the use of IL-1 blockade in CRC and urges caution against a ''one size fits all'' global blockade of IL-1R signaling. We propose that in some microbe-rich cancers a complete inhibition of IL-1R signaling would not be as beneficial as specific blockade of this axis in T cells or epithelial cells, for example via antibody-based approaches that deliver IL-1 blockers specifically to T cells. Such next-generation approaches will allow blocking IL-1R signaling only in ''pro-tumorigenic'' cell types, while preserving ''anti-tumorigenic,'' protective signaling. Alternatively, approaches aimed at enhancing intra-tumoral anti-bacterial functions or depleting potentially pathogenic microbiota should be considered along with IL-1R signaling blockade. Finally, the role of individual IL-1a and IL-1b ligands and the potential for their neutralization over complete IL-1R blockade needs to be further assessed.
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STAR+METHODS EXPERIMENTAL MODELS Mice
Using Il1r1 f/f conditional allele (Bruttger et al., 2015) , we generated a panel of mice in which IL-1R1 expression was ablated in colonic epithelial and cancer celIs. Il1r1 f/f mice were crossed to different Cre-recombinases to get cell-specific deletion of Il1r1 gene, , CDX2Cre (CPC) and CDX2ERT mice have been provided by E. Fearon. Ly6GCre ('catchup'') mice were from Matthias Gunzer (Hasenberg et al., 2015) . For further information and MGI numbers identifying aforementioned mouse strains please see Key Resources Table. For conditional ablation of IL-1R1 in colonic epithelial and tumor cells of CPC-APC mice, Il1r f/f Apc f/f mice were crossed to CDX2Cre-Il1 D/WT mice, where the null (D, deleted) Il1r allele is derived from the whole-body knockout strain. All mice were maintained in filter-topped cages on autoclaved food and water at the Fox Chase Cancer Center Animal Facility (FCCC), and all experiments were approved by FCCC IACUC. All experiments used co-housed littermates, unless indicated otherwise, so that consistency of common microflora and genetic background/alterations would be ensured. For tamoxifen-inducible tumorigenesis, CDX2ERT-Apc f/f mice were given 2 injections of tamoxifen 2 mg and 1.5 mg per mouse (Sigma; dissolved in 5% ethanol, 95% corn oil (Sigma)) intraperitoneally (i.p.) every other day. Mice were sacrificed 4-6 weeks after the last dose of tamoxifen for histological analysis and tumor statistics.
Bone Marrow Transplantation
Six-to eight-week-old recipient mice were irradiated twice (600 rad and 500 rad) using cesium irradiator at FCCC during one day to achieve a lethal dose and intravenously injected with a single-cell suspension of donor bone-marrow cells. Recipients were co-housed littermates, which were transplanted with both gene-deficient and wild-type bone marrow. After transplantation, the recipients were placed on neomycin and polymixin B in drinking water for two weeks, followed by transfer to dirty cages that were from the same room and rack to reconstitute potentially depleted microbiota. Mice were sacrificed and analyzed for tumor development 4 months after transplantation; for inducible CDX2ERT-Apc f/f model mice were allowed to reconstitute BM, injected with tamoxifen (as above) and then allowed to develop CRC for 4-6 weeks.
Antibiotic treatment
To deplete gut microbiota mice were given mix of antibiotics in drinking water for 4 weeks. Water was changed every 3-4 days. Antibiotics cocktail included:
. Antibiotics treatments started after last injection of Tamoxifen and after 4 weeks of treatment mice were sacrificed for tumor analysis.
Immune cells isolation, ex vivo cell stimulation, Flow Cytometry and Cell Sorting Lamina propria lymphocytes (LPL) and Intraepithelial lymphocytes (IEL) cells from colonic tumors and normal tissues were isolated. Briefly, colonic tumors and normal tissues were cut into small pieces and briefly washed in 1mM DTT-HBSS, followed by mechanical shaking with 10mM EDTA-HBSS in a shaker (200 rpm) at 37 C for 20 min for 2 rounds total. Then IEL/IEC fraction was passed through a metal mesh and cells collected, while the remaining tissue was digested in 20 mL of Collagenese Type VIII (Sigma) solution in 1xHBSS in the shaker (180rpm) at 37 C for 30 min. Digested tissue was passed through a 70 mm Cell Strainer and cell suspension was collected (unpurified LPL). IEL/IEC and LPL fractions were further enriched by Percoll gradient centrifugation (20min, 2200rpm, no brake; Percoll gradient 40%/ 80% in HBSS). Lymphoid cell ring on a border of fraction was collected, washed and re-suspended in FACS buffer (1xPBS, 1mM EDTA, 2%FBS). Single cells suspension was subjected then to flow cytometry analysis, cytokine stimulation or cell sorting.
To detect intracellular cytokine expression in tumor infiltrating immune cells, isolated LPL and IEL cells were stimulated in RPMI 1640 High glucose activation media (10% FBS, 1x Glutamax, HEPES 1mM, 1x penicillin/streptavidin, 1x cell culture b-mercaptoethanol) for 5.5 hours with PMA 500 ng/mL and ionomycin 100 ng/mL at 37 C. To inhibit protein transport, Monensin and Brefeldin A at concentration 5 mg/mL were added in activation media after first 40 min of stimulation. Cells were collected, stained for surface markers, washed, fixed and permeabilized (BD Cytofix/Cytoperm Kit), stained for intracellular cytokines and analyzed by flow cytometry. All flow samples were acquired on a LSRII (BD Biosciences) and analyzed using FlowJo v. 10 (TreeStar). For cell sorting, samples were stained and sorted on BD FACSAria II sorter (BD Biosciences).
Intestinal epithelial cell isolation for protein analysis Colonic tumors and normal tissues were cut into small pieces followed by mechanical shaking (200 rpm) with 10mM EDTA in Ca 2+ Mg 2+ free 1x HBSS at 4 C for 15 min; 3 rounds total. After each round of shaking cells were vortexed for 20 s and put through metal strainer; cell suspension was collected and centrifuged at 1600 rpm for 10 min at 4C. Pellets were resuspended in ice cold PBS containing inhibitors of proteases and phosphatases and then subjected to protein nuclear extraction.
Nuclear protein extraction and western blot
Intestinal epithelial cells (IEC) were re-suspended in buffer A (10mM HEPES (pH = 7.9), 10mM KCl, 10mM MgCl 2 , 1mM DTT and 1x protease inhibitor cocktail (Roche)) and incubated on ice for 15 min followed by adding 10% NP40 to total concentration of 1%. Content was vortexed for 20 s and spun down at 12000 rpm for 30 s. Supernatants were collected as cytoplasmic protein extracts. Pellets were re-suspended again in buffer A and centrifuged. Washed pellets were re-suspended in buffer C (20mM HEPES (pH = 7.9), 25% Glycerol, 0.4M NaCl, 1.5mM MgCl 2 and 1x protease inhibitor cocktail) and incubated on ice for 15 min, then centrifuged at 12000 rpm for 5 min. Supernatants were collected as nuclear protein extract, mixed with RIPA buffer with protease inhibitors and subjected to western blot analysis with anti-NF-kB p65 (Cell Signaling) antibody and anti-Histone H3 (Cell Signaling) antibody for loading control.
In Vivo Treatment with Anakinra Mice were injected intraperitoneally for three consecutive days with 2.5 mg recombinant human IL-1Ra (Anakinra/Kineret, Rx, FCCC Pharmacy), or PBS for control group.
RNA extraction and quantitative Real Time-PCR Analysis
Total RNA was extracted with the RNAeasy Plus kit (QIAGEN) and reversely transcribed using IScript kit (Biorad). Quantitative RT-PCR (qRT-PCR) was performed with iTaq Universal SYBR Green Supermix (Biorad) on a Biorad CFX96 machine. Expression data were normalized to RpL32 mRNA levels. The data are presented in arbitrary units and were calculated as 2(Ct (RpL32 -gene of interest)). Primer sequences generally were obtained from the NIH Mouse qPrimerDepot website repository and are listed in Key Resources Table. Analysis of Cytokine Production by Multiplex or ELISA Small pieces of tumors were incubated for 24h in complete RPMI 1640 media. Supernatants were collected and cytokine secretion was measured by mouse Procarta 17-Plex cytokine array (eBioscience) on MagPix instrument (Luminex) according to manufacturer's instructions. For ELISA analysis of IL-17A, colonic tumors were cultured in DMEM containing 10% fetal bovine serum (FBS) and antibiotics overnight, and supernatant was analyzed with IL-17A ELISA kit (eBioscience). Cytokine concentration was normalized to the weight of tumors in each well.
Immunohistology and immunofluorescence
For immunohistology, immediately after euthanasia, colon rolls were fixed with 10% buffered formalin and kept overnight at RT. After fixation samples were transferred in 70% ethanol prior to paraffin embedding. 5 mm thick sections were cut in the sagital plane for staining with hematoxylin and eosin. Images were acquired and quantified with slide scanning Vectra microscope (Vectra).
Sections were de-paraffinased in 4 changes of xylene, then dehydrated and re-hydrated in 100%->70% ethanol changes. Antigen retrieval of samples was performed in 1x Citrate buffer (10mM Citrate, 0.05% Tween 20, pH 6.0) at 95C for 1h. Then slides were rinsed in dH 2 O, dehydrated in 100% ethanol, then blocked with 3% H 2 O 2 in PBS, rinsed with water, blocked in PBS-5% BSA-5% normal goat serum for 20 min, then incubated with primary antibody anti-Ki-67 (1:250) or anti-p-STAT3 (1:100) overnight at 4C, then washed 3x in PBS -1% BSA. Next, secondary biotinylated anti-rabbit antibodies were applied at 1:200 dilution and incubated at RT for 1h, rinsed in PBS. Next, Streptavidin-HRP was applied at dilution 1:250 in PBS-1%BSA for 30 min at room temperature, slides were washed 3x in PBS, then developed with chromogen DAB solution for 7 min at room temperature. Next, slides were rinsed and counterstained with hematoxylin, rinsed with water and immersed into 0.25% ammonium hydroxide, dehydrated with 4 changes of ethanol 70%->100%, followed by 4 changes of xylene for 5 min each, and mounted.
Images were acquired with slide scanning Vectra microscope (Vectra). Immunofluorescencent staining was performed in the same way with IHC protocol with few exceptions-blocking buffer was containing 5% goat serum, 10% BSA, 0.1% Triton X-100 in 1xPBS. Goat-anti-rabbit AF488 was used for secondary antibody, and then samples were washed follow by staining with DAPI for 10 min at RT. Slides were mounted with VectorShield and covered with coverslip. After drying for 1-2h at RT slides were analyzed on Leica SP8 Confocal Microscope.
Whole tissue IF staining for bacteria with Yo-Yo 1 dye For whole-mount staining, colons were fixed in buffered 4% paraformaldehyde for 8h at 4C. Tissues were permeabilized by incubation with 0.5% (wt/vol) saponin, 2% (vol/vol) FBS, and 0.09% (wt/vol) sodium azide in PBS for at least 18 hours. The same buffer was used for subsequent incubations with antibodies. Colon fragments were incubated with AlexaFluor 647 phalloidin (1:200) and Yo-Yo1 (1:500) dye for 12-16 hours at 4C followed by 1-2 hour incubation at 37C. Samples were washed with PBS, mounted flat in PBS and imaged with water dipping lens by Leica SP8 Confocal microscope. 
Bacteria killing assay
Sorted neutrophil populations from peritoneal cavities, spleen or bone marrow were pretreated with 100ng/mL of recombinant IL-1b for 1h in complete antibiotic free RPMI media at 37C. Meanwhile, bacteria (suspension of E. coli) were grown to the approximately 1.6 3 10 8 cells/mL (OD 600 nm = 0.2) or stool bacteria were prepared to similar concentration by disrupting feces in ice cold PBS and filtering through 40 mcm strainer. Next, E.coli or ''bulk'' stool bacteria was incubated for 30 min with 20% of normal mouse serum for opsonization and after that added to neutrophils in the approximate of 50:1 bacteria/neutrophil ratio, incubated for 1 h at 96-well plate, then spin down for 5 min at 1500 rpm and lysed in DI water with 0.1% Triton-100. Lysates were diluted serially (1:10, 1:100, 1:1000) for plating on LB or blood agar. Plates were incubated in anaerobic (BD BBL GasPak Anaerobic Systems) or regular aerobic conditions overnight at 37C. Colonies were counted manually.
Phagocytosis assay
Sorted neutrophil populations from peritoneal cavities or spleens were pretreated with 100ng/mL of recombinant IL-1b for 1 h in complete RPMI media at 37C, then suspension of zymosan beads conjugated with Alexa Fluor 594 dye (Invitrogen) or Salmonella-GFP was added and cultured with neutrophils for 2h. Cell suspensions were transferred on Poly-L-lysine coated glass slides, fixed with 4% PFA for 5 min and stained with anti-Ly6G (A18)-FITC or -APC antibodies in 1:75 ratio for 20 min and counterstained with DAPI for confocal imaging.
Microbiome analyses
Bacterial DNA was isolated from a fecal content or epithelial ''shakes'' of various naive or CRC bearing mouse strains. Samples were homogenized with RNase/DNase free 2.8mm Ceramic Beads using Omni Bead Ruptor 24 in ASL buffer (Stool lysis buffer; QIAGEN) followed by DNA isolation using QIAamp DNA stool Mini Kit (QIAGEN) according to manufacturer's protocol. Library preparation, sequencing and data analysis were carried out essentialy as previously described (Fatkhullina et al., 2018) . Briefly, QPCR was carried out using universal or bacterial strain-specific primers for 16S rRNA genes. The V4 region of the 16S rDNA gene using two round amplification PCR using Phusion High-Fidelity DNA-polymerase (NEB) with 100ng of input DNA. First round PCR (15 cycles): 515F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG 806R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC Second round PCR (10 cycles) with i5 and i7 Illumina barcode sequences: AATGATACGGCGACCACCGAGATCTACAC-i5-TCGTCGGCAGCGTC CAAGCAGAAGACGGCATACGAGAT-i7-GTCTCGTGGGCTCGG Amplicones were purified between and after the PCR reactions with Agencourt AMPure XP (Beckman Coulter, Inc.) and libraries were quantified using KAPA Library Quantification Kit for Illumina Platforms (Kapa Biosystems) and size was estimated using Agilent Tapestation 4200 (Agilent). Libraries were pooled at equimolar concentration using Epmotion 5075 tmx automatic liquid handling machine (Eppendorf) and sequenced with 5% PhiX library added to the pool on Illumina MiSeq machine according to manufacture instructions using v3 kit (600 cycles). Fastq files were generated on Basespace (Illumina). On average 100,000 reads were obtained per sample, and after quality control filtering; on average 90,000 reads per sample were processed further. Chimeric sequences were filtered out of the FASTQ files containing the 16S rRNA gene sequences using the USEARCH (version 8.1) utility's UCHIME implementation and the 'gold' database (version microbiomeutil-r20110519). The reads, thus filtered, were then binned into operational taxonomic units (OTUs) at 97% similarity using USEARCH's cluster_otus command. QIIME (1.9.1) scripts were used to classify and align the obtained OTUs. The assign_taxonomy.py script was used to assign taxonomy using the default RDP method and GreenGenes database.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are presented as mean ± SEM, as indicated in the legend of each figure. The significance of the differences between groups was evaluated using unpaired t test, p value < 0.05 was considered significant. Statistical parameters including the precision measures (mean ± SEM) and statistical significance are reported in the Figures and the Figure Legends when necessary. In figures, asterisks denote statistical significance (*, p < 0.05; **, p < 0.01; ***, p < 0.001), unless indicated otherwise. Experiments were repeated at least twice. Statistical analysis was performed in GraphPad PRISM 6.
For microbiome analyses the statistical differences between the groups were estimated with non-parametric Mann-Whitney test, PERMANOVA test and p values were corrected for multiple tests using q-value 0.05 as a cutoff and data was visualized using heatmaps and PCA plots (Partek 6.6).
DATA AND SOFTWARE AVAILABILITY
The accession number for the raw data files for 16SRNA microbiome sequencing analysis reported in this paper is NCBI BioProject: Accession number PRJNA480459, SRA Accession number SRP152945.
